The present analysis further characterizes the association between elevated inflammatory biomarkers and breast cancer relapse as being perhaps more relevant in subjects with HR+/HER2− tumors, and potentially less relevant in HER2+ tumors. Here, ERBB2 is linked to breast carcinoma.